Who are ivermectin cream 0.5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Egaten, Albenza, PRAZIQUANTEL, (+/-)-Oxamniquine, Vermox, Bovizole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-cream-0-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

ivermectin cream 0.5% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ivermectin cream 0.5% (ivermectin cream 0.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthelmintic. Area: Dermatology.

phase 3 anthelmintic Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

ivermectin cream 0.5% (ivermectin cream 0.5%) — Rabin Medical Center. Ivermectin cream 0.5% works by killing Demodex mites and other microfilariae that cause rosacea.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ivermectin cream 0.5% TARGET	ivermectin cream 0.5%	Rabin Medical Center	phase 3	anthelmintic
Egaten	TRICLABENDAZOLE	Novartis	marketed	Anthelmintic [EPC]	Transthyretin	2019-01-01
Albenza	ALBENDAZOLE	Impax Labs Inc	marketed	Anthelmintic [EPC]		1996-01-01
PRAZIQUANTEL	PRAZIQUANTEL		marketed	Anthelmintic [EPC]		1982-01-01
(+/-)-Oxamniquine	OXAMNIQUINE		marketed	Anthelmintic		1980-01-01
Vermox	MEBENDAZOLE		marketed	Anthelmintic [EPC]	Vascular endothelial growth factor receptor 2	1974-01-01
Bovizole	THIABENDAZOLE		marketed	Anthelmintic	Cytochrome P450 1A2	1967-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthelmintic class)

Rabin Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ivermectin cream 0.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-cream-0-5. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing